Incyte | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 52.37M 28.79M 2025-03
Alnylam Pharmaceuticals USD 1.08B 110.65M 2025-03
Amgen USD 23.01B 91M 2025-03
Biogen USD 5.3B 231.4M 2025-03
BioMarin Pharmaceutical USD 628.21M 21.22M 2025-03
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Eli Lilly USD 30.07B 1.69B 2025-03
Exelixis USD 403.77M 9.42M 2025-01
Gilead Sciences USD 12B 279M 2024-12
Incyte USD 1.89B 244.96M 2025-03
Ionis Pharmaceuticals USD 250.29M 59.02M 2025-03
MacroGenics USD 55.53M 3.78M 2024-12
Merck USD 28.42B 1.17B 2024-12
Moderna USD 1.6B 602M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Incyte Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.